Stay updated on Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.

Latest updates to the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check77 days agoChange DetectedThe webpage has undergone significant updates, including the addition of a new study on Soft Tissue Sarcoma, with a focus on the collaboration with Merck Sharp & Dohme LLC and a revision update. Key details about the study's objectives and inclusion criteria have been removed, which may impact the understanding of the study's purpose.SummaryDifference45%
- Check84 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.